Dato-DXdPREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease

Sponsor:

UNC Lineberger Comprehensive Cancer Center

Code:

NCT07069595

Conditions

Breast Cancer

Residual Disease

Triple Negative Breast Cancer (TNBC)

Stage II/III

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Datopotamab deruxtecan

Circulating tumor DNA (ctDNA) testing

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-24. This information was provided to ClinicalTrials.gov by UNC Lineberger Comprehensive Cancer Center on 2026-04-22.